

Anti-Cancer Drugs 2008

Keyword Index to Volume I9

- 2-5A antisense oligonucleotides, 329
5-fluorouracil, 447, 631
5-methyltetrahydrofolate, 697
6-amino-4-quinazoline, 777
9-nitrocampothecin, 805
13-*cis*-retinoic acid, 201
17-allylamino-17-demethoxygeldanamycin, 681
143B osteosarcomas cell line, 257
- ABCG2, 411
Abraxane, 899
acetylcholine receptors, 655
acute, 495
acute leukemia, 705
acute myeloid leukemia, 45, 1007
acute promyelocytic leukaemia treatment, 812
adeno-associated virus, 783
adhesion, 55
adrenocortical carcinoma, 637
advanced breast cancer, 421
advanced gastric cancer, 283, 535, 825, 1013
AKT, 401, 681, 705
alkylating agent, 295
alkylphospholipids, 65
alpha-tocopherol ether-linked acetic acid analog, 175
amonafile, 23
amphibians, 931
amsacrine, 45
anastrozole, 339
androgen, 583
angiogenesis, 65, 427
anilinoacridine, 381
anoikis, 55
anthracyclines, 1, 317
anti-p53 antibodies, 317
antibiotic therapy, 673
antibody therapy, 599
anticancer, 381, 697, 931
anticancer drugs, 517
antineoplastic combined chemotherapy protocols, 745
antioxidant, 115
antitumor agents, 789
apogossypolone, 967
apoptosis, 65, 115, 125, 159, 189, 247, 381, 401, 477, 503, 553, 689, 697, 871, 967, 975
apoptosis-inducing factor-dependent pathway, 553
aromatase inhibitors, 339
arsenic trioxide, 812
ATP analog, 391
autonomic nervous system, 655
- β-adrenergic receptors, 655
Bax, 871
Bayesian estimation, 267
Bcl-2, 871, 967
Bcl-2 and Bax, 247
Bcl-2 phosphorylation, 553
bevacizumab, 435
bevacizumab (Avastin), 427
BIBR1532, 329
biliary tract carcinoma, 631
biodistribution, 721, 999
biomarker, 899
bisphosphonates, 645
biweekly application, 541
bladder contracture, 325
bone tumors, 257
bortezomib, 777
BRACO-19, 329
- brain cancer, 859
brain metastasis, 832
brain tumor, 133
breast cancer, 317, 447, 689, 733, 766
breast cancer cell lines, 359
breast neoplasms, 1
bromodeoxyuridine–DNA flow cytometry, 359
buparfen, 931
- c-myc, 477
C6 glioma, 859
cancer therapy, 401
capecitabine, 77, 435, 447, 819, 825
carboxy-terminal domain, 565
cardiac toxicity, 753
cardiac uptake, 729
cardiomyopathies, 1
caspase, 381, 967
caspase-3, 247, 871
caspase-8, 766
catalase, 975
CD38, 599
CD117, 607
celecoxib, 175
cell cycle, 125, 697, 891
cell cycle arrest, 167, 593
cell cycle kinetics, 359
cell differentiation, 713
cell growth, 689
cell type-specific signaling, 655
central nervous system, 917
central nervous system tumor, 859
cerebrospinal fluid, 832
cerebrovascular accident, 97
cervix, 713
cetuximab, 99, 435
CH1104I, 957
chemotherapeutic drugs, 517
chemotherapy, 85, 183, 221, 325, 541, 631, 637, 921, 941
Chlamydia psittaci, 761
chronic myelogenous leukemia, 975
cisplatin, 97, 159, 201, 369, 583, 621, 721, 793, 927
clinical tumor response, 317
clodronate, 391
coculture assay, 143
colon cancer, 447
colorectal adenocarcinoma, 55
colorectal liver metastases, 17
colorectal neoplasms, 745
combination, 745
concomitant chemoradiotherapy, 991
continuous infusion of 5-fluorouracil/leucovorin, 283
copper, 125
CPT-11, 749
Cremophor, 275
cyclins, 359
cyclooxygenase-2, 891
cyclooxygenase-2 deletion, 891
cyclooxygenase-2 inhibitor, 891
cyclophosphamide, 167
cyclosporin A, 275
cystectomy, 325
cytochrome c release, 967
cytochrome P450 3A4, 295
cytolysins, 517
cytotoxic bombesin, 349
cytotoxic luteinizing hormone-releasing hormone, 349
cytotoxic somatostatin, 349
cytotoxicity, 805
- dacarbazine, 201
dendrimer, 143
derivative, 167
dihydroartemisinin, 247
dihydropyrimidine dehydrogenase, 819
diphtheria antibodies, 1007
diphtheria fusion proteins, 1007
dithiocarbamate, 593
docetaxel, 421, 465, 535, 899, 1013
dose-density, 421
doxifluridine, 911
doxorubicin, 1, 583, 793
drug delivery, 183, 721
- E-cadherin, 487
ECF regimen, 837
efficacy, 283
efflux protein, 411
elderly, 289
endometrial carcinoma, 115
endonuclease G, 503
endothelial cells, 65
enzastaurin, 77
epidermal growth factor receptor, 9, 435, 465, 739
epidermal growth factor receptor inhibitors, 99
ERCC1, 983
erlotinib, 209, 435, 465
estramustine, 645
estrogen, 583
estrogen receptor, 339
exemestane, 339
exposure–response relationship, 37
extracellular signal-regulated kinase 1/2, 681
extracellular signal-regulated kinase-1/2 signal pathway, 593
- first-line therapy, 753
fluoropyrimidine, 447
food effect, 209
formulation, 275
fotemustine, 613
- γ-secretase inhibitor, 477
G-quadruplex interacting ligands, 329
galloyl cyclic-imide derivative, 957
gastric cancer, 159, 819, 885, 921
gastrointestinal stromal tumors, 607
gefitinib, 527, 739
gemcitabine, 289, 309, 431, 435, 621, 749
gene expression study, 257
gene therapy, 133
glioblastoma multiforme, 613
gliomas, 133, 517
glycoproteins, 885
glycyrol, 503
GRN163L, 329
growth factors, 689
- hand–foot syndrome, 447
head and neck cancer, 465, 739
heat shock protein 90, 681
heme oxygenase, 495
hepatocarcinoma H₂₂, 167
hepatocellular carcinoma, 837, 891
HepG2, 477
HER2 overexpression, 832
high-dose methotrexate, 267
high-grade gliomas, 613
histone deacetylase inhibitor, 849
HKI 46F08, 849
- HL-60, 697
Hodgkin's lymphoma, 309
hormonal therapy, 221, 941
hormonal treatment, 339
hormone refractory prostate cancer, 645
human breast cancer, 871
human epidermal growth factor receptor-2, 899
human hepatocarcinoma cell, 401
human kidney epithelial 293T, 503
- ifosfamide, 295
imatinib, 527, 607, 975
immortalized cells, 713
immunoliposome, 599
immunotherapy, 133, 325
in vitro, 65
in-vitro antiproliferative activities, 789
induction therapy, 607
inflammation, 503
interferon, 527
interleukin-2, 201
interleukin-6, 777
interleukin-12, 133
intraperitoneal, 37
intrathecal therapy, 917
invasion and metastasis, 957
isoquinoline, 859
- Janus kinase 2, 565
Jun N-terminal kinase, 189
Jurkat, 477
- kidney failure, 495
kidney toxins, 495
kinase inhibitory activities, 789
- LA-12, 369
lethal dose 50, 167
letrozole, 339
leucovorin rescue, 267
leukemia, 247, 411
leukocytotoxic effect, 167
lignan, 487
lipid formulation, 721
lipofection, 783
lipoplatin, 983
liposomal doxorubicin, 991
liposomal idarubicin, 729
LRP, 983
lung cancer, 9, 783
LY317615, 77
- m-TOR, 705
malignant glioma, 991
malignant pleural mesothelioma, 841
MALT lymphoma, 761
mammalian target of rapamycin, 1019
mammalian target of rapamycin inhibitors, 235
management, 637
matrix metalloproteinases, 957
MDR-1, 983
medulloblastoma, 849
melanoma, 189
membrane fluidity, 766
meningeal carcinomatosis, 832
meningeal lymphomatosis, 917
meridianins, 789
metabolism, 391
metastases, 637
metastasis, 235

- metastatic breast cancer, 753, 832
metastatic melanoma, 201
methionine synthase, 697
methotrexate, 143, 793
methyl jasmonate, 573
methylation, 487
mevalonate pathway, 391
microarray, 257, 503
mitochondria, 967
mitochondrial transmembrane potential, 871
mitogen-activated protein kinase, 55, 766
mitomycin C, 303
mitoxantrone, 325, 421
monoclonal antibodies, 99, 235
multidrug resistance, 257, 793
multiple myeloma, 777
myxoid chondrosarcoma, 1019
- N^1 , N^{11} -diethylnorspermine, 359
N-acetyl-transferase 2, 23
N-methyl-*N'*-nitro-*N'*-nitrosoguanidine, 885
nanocapsules, 721
nanomedicine, 999
nanoparticles, 183, 805, 899
naringenin, 885
necrosis, 159
neoadjuvant chemotherapy, 317, 733
neoplasm, 143
neuroblastoma, 125, 573, 849
non-Hodgkin lymphoma, 917
non-Hodgkin's lymphoma, 673
non-small cell lung cancer, 749, 983
nonmelanoma skin cancer, 175
nonseminomatous germ cell tumor, 97
nonsmall cell lung cancer, 289
norcantharidin, 55
nordihydroguaiaretic acid, 487, 713
noscapine, 553
Notch signaling, 477
noxa, 159
nuclear factor-kappa B inhibitor, 777
nucleoside analogs, 329
numonafide, 23
- ocular adnexal, 761
ocular and adnexal localization, 673
oncogenesis, 503
oral delivery, 999
oral paclitaxel, 275
oral squamous cell carcinoma, 85
- osteosarcoma, 257, 267
ovarian cancer, 541
ovarian carcinoma xenograft, 721
oxaliplatin, 37, 283, 535, 631, 745, 825, 1013
OXi4503, 17
oxidative damage, 885
oxidative stress, 975
- p38 signal pathway, 593
p53, 189, 369, 381, 503
p53/47, 369
paclitaxel, 733, 899, 911
paconol, 401
palliative chemotherapy, 535
pancreatic cancer, 435
particle bombardment, 783
pathology, 607
pathophysiology, 927
pegylated α -interferon, 201
pegylated liposomal doxorubicin, 541, 733
peptide nucleic acids, 329
peptides, 931
perfused rat heart, 729
perinucleolar compartment, 23
permeability, 17
peroxisome proliferator-activated receptor α / γ , 151
pharmacokinetics, 77, 209, 267, 275, 295, 753, 805
phase I, 77
phase I clinical trial, 411
phase I study, 289
phase I trial, 295
phase II study, 85
phase I/II study, 739
phase III studies, 221, 941
plant compounds, 766
platinum-refractory disease, 541
platinum-protein and platinum-DNA binding, 621
poly (D,L-lactic-glycolic acid), 805
poly(ADP-ribose) polymerase-1, 381
polyamine analogue, 359
polymer, 133
poor performance status, 431
pore-forming proteins, 517
predictive factors, 221, 941
progesterone receptor, 339
proliferating cell nuclear antigen, 573
proliferation, 477
proteasome inhibitor, 115
protein kinase C, 77, 841
- PTEN, 401
PTK787/ZK 222584, 45
PUMA, 189
purvalanol A, 565
pyrrolidine dithiocarbamate, 125
- QGY-7703, 593
- radiotherapy, 673
rapamycin, 681, 1019
rats, 885
receptor tyrosine kinase, 841
reconstituted (synthetic) high-density lipoprotein, 183
recurrent, 911
regulation of cancer cell by neurotransmitters, 655
relapse, 613
renal cell cancer, 235
renal cell carcinoma, 527, 983
resection, 607
RET, 547
rituximab, 673
RNA polymerase II, 565
RNase, 931
RNK-16 large granular lymphocytic leukemia, 999
- S-1, 85, 289, 303, 745, 921
S phase, 359
salvage chemotherapy, 1013
sarcomatoid renal cell carcinoma, 431
second-line therapy, 303, 749
second-line chemotherapy, 613
serum, 812
signal transducer and activators of transcription 3, 9, 565
SK-Hep-1, 349
SKH-1 hairless mice, 175
skin erosion, 217
SPARC, 899
spermine analogue, 871
squalenoyl gemcitabine, 999
statin, 705
stomach cancer, 303
sulfur-containing compounds, 621
sunitinib, 547
survivin, 573, 975
SW620 colon carcinoma cells, 37
synergy, 705
systemic chemotherapy, 837
systemic treatment, 235
- T-cell lymphoma, 583, 793
tamoxifen, 339
targeted agents, 645
targeted drug delivery, 143
targeted therapies, 689
targeted therapy, 221, 917, 941
taxane, 317, 899
telomestatin, 329
temozolomide, 613
the mammalian target of rapamycin, 681
therapy, 841
thermal, 37
thio-phosphoramidates, 329
thrombosis, 927
thymidine phosphorylase, 819
thyroid cancer, 547
tissues, 812
topoisomerase, 381, 411
topoisomerase II, 151
topotecan, 411
toxicity, 283, 295
trace elements, 812
transferrin receptor, 247
translational research, 221, 941
trastuzumab, 753, 832
treatment sequence, 465
tubulin-binding agent, 553
tumor, 477
tumor cytotoxicity, 583
tumor progression, 793
tyrosine kinase inhibitors, 235, 739
tyrosine kinase inhibition, 527
- U937, 967
ultraviolet-induced skin cancer, 175
urethra, 427
urothelial cancer, 427
- vascular endothelial growth factor, 45, 217, 427, 435
vascular toxicity, 97
vasculature, 17
venous access device, 217
vinblastine, 201
vincristine, 189
vinorelbine, 753
vitamin E analog, 175
VP16, 151
- X-linked inhibitor of apoptosis protein, 573
xenograft, 899
- zoledronic acid, 391